Alvotech (ALVO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN LU2458332611
Alvotech financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 489.68 m USD | 586.32 m USD |
| Gross profit | 304.37 m USD | 350.76 m USD |
| Operating income | 69.64 m USD | 78.21 m USD |
| EBIT | -63.58 m USD | 285.54 m USD |
| Net income | -231.86 m USD | 27.92 m USD |
| Diluted EPS – continuing operations | -0.87 USD | 0.10 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
More stocks
- Business intelligence of Oriental Nations Corp Ltd (300166.SZ)
- Hainan Drinda Automotive Trim Co Ltd (002865.SZ)
- Tsubakimoto Chain Co (6371.T)
- Nippon Gas Co Ltd (8174.T)
- Bloks Group Ltd (325.HK)
- PHOTRONICS INC (PLAB)
- Ganzhou Tengyuan Cobalt New Material Co. Ltd. (301219.SZ)
- Saga PLC (SAGA.L)
- Ignitis Grupe AB (IGN1L.VS)
- SBT Ultrasonic Technology Co. Ltd. A (688392.SS)
- Grupo Gigante S. A. B. de C. V (GIGANTE.MX)
- Ningbo PIA Automation Holding Corp. A (688306.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.